Table 2. Examples of Anti-Androgens Approved by the Food and Drug Administration (FDA) agents to treat prostate cancer*.
Drug name | Mechanism of action | Indication Examples |
---|---|---|
Leuprolide acetate | GnRH** agonists | Palliative treatment of advanced prostatic cancer. |
Goserelin acetate | GnRH agonists | Palliative treatment of advanced prostatic cancer. |
Triptorelin pamoate | GnRH agonists | Palliative treatment of advanced prostatic cancer. |
Histrelin acetate | GnRH agonists | Palliative treatment of advanced prostatic cancer. |
Degarelix acetate | GnRH antagonists | Palliative treatment of advanced prostatic cancer. |
Bicalutamide | Binds to androgen receptor | Metastatic prostate cancer |
Flutamide | Competes for AR the and dihydrotestosterone for the androgen receptor | “”” |
Nilutamide | Blocks AR | Advanced prostate cancer |
Abiraterone acetate | CYP17A1 inhibitor | Metastatic castration-resistant prostate cancer who have received prior docetaxel. |
Enzalutamide | Androgen receptor inhibitor | Metastatic castration-resistant prostate cancer who have received prior docetaxel. |
Radium Ra 223 dichloride | Alpha-particle emitting | Symptomatic bone metastases and no known visceral metastatic disease. |
Data from www.fda.gov (Accessed August 11, 2014).
AR = androgen receptor; GnRH: gonadotropin releasing hormone.